Business Context and Reporting Period
This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) covers events occurring on December 31, 2024, and January 7, 2025. The Company is a Delaware corporation listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance and corporate announcements rather than financial performance data.
Material Changes
- Nasdaq Non-Compliance: On December 31, 2024, the Company received notice from Nasdaq that its common stock failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days (November 15, 2024, to December 30, 2024).
- Compliance Timeline: The Company has an initial 180-day compliance period ending June 30, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- Delisting Risk: Failure to regain compliance by the deadline may result in delisting, though the Company may be eligible for an additional 180-day period if it meets other listing standards and considers a reverse stock split.
Outlook, Risks, and Management Commentary
- Management Action: The Company stated it will monitor the closing bid price and may consider available options, including a reverse stock split, to regain compliance.
- Investor Relations: CEO Dr. Anatoly Dritschilo is scheduled to participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025.
- Risks: There is no assurance the Company will regain compliance with the Minimum Bid Price Requirement or maintain other Nasdaq listing requirements. Delisting remains a possibility if compliance is not achieved.
Investor Verification Checklist
- Verify the current closing bid price of SHPH stock to assess progress toward the $1.00 threshold.
- Monitor future filings for announcements regarding a potential reverse stock split.
- Review the Company's cash position in subsequent filings (e.g., 10-K or 10-Q) to evaluate liquidity given the lack of financial data in this 8-K.
- Confirm the status of the Company's appeal rights should delisting proceedings commence after June 30, 2025.